- |||||||||| DSP-FC 216 / Kahr Medical, Thomas Jefferson University
DSP216 (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_784; 0155-17-HMO). Samples were received anonymously, and consent was not required.Download figure Open in new tab Download powerpoint Abstract 509 Figure 1
- |||||||||| DSP-FC 216 / Kahr Medical, Thomas Jefferson University
DSP216 blocks HLA-G and CD47 signaling toward immune cells and restores anti-cancer activity () - Feb 16, 2024 - Abstract #ITOC2024ITOC_19; DSP216 prevents HLA-G mediated upregulation of the M2 marker CD163 on macrophages and eliminates HLA-G + CD47 + cancer cells by promoting macrophage-mediated phagocytosis and NK cell-mediated cytotoxicity. DSP216 is a novel bifunctional therapeutic that has the potential to reverse immunosuppressive signaling and unleash innate anti-cancer immune responses.
- |||||||||| DSP-107 / Kahr Medical
Journal: DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. (Pubmed Central) - Mar 31, 2022 DSP107 is a novel, CD47 and 4-1BB targeting fusion protein with a differentiated safety, binding and pharmacodynamic profile compared to other CD47 and 4-1BB targeting agents. DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells () - Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_81; DSP107 is a first-in-class drug candidate that can be used as a monotherapy or in combination with tumor-targeting monoclonal antibodies to trigger induction of anti-cancer immunity. DSP107 is currently tested in IND-enabling studies and clinical development is planned to commence in 2020.
|